Ubjects with SLe Pregnancy registry observational in SLe sufferers Safety, tolerability
Ubjects with SLe Pregnancy registry observational in SLe sufferers Security, tolerability, immunogenicity of belimumab in SLeDrug Design, Development and Treatment 2015:9 iv iii iii iv iii iv() iii ii ii iii iii ii iv() Nov-10 Jun-11 iii ii ii ii ii ii ii Completed Finished Recruiting Finished Stohl w, 2013 No study outcomes posted Recruiting No research Plasmodium Formulation results posted Jan-05 Time to to start with relapse Percentage of individuals with ACR20 response at week 24 Adjust in modified Rodnan Skin Score at 48 weeks Terminated At ClinicalTrials.gov Ongoing No research effects posted Completed van vollenhoven RF, 2012; Stohl w, 2012 Finished Navarra Sv, 2001 Recruiting No research success posted Recruiting No research results posted Completed Furie R, 2008; Struemper H, 2013 Recruiting No research outcomes posted Finished wallace DJ, 2009; Furie, RA, 2009 Recruiting No review results posted Recruiting No research outcomes posted Ongoing No research success posted Recruiting No review final results posted Ongoing No research results posted Completed No examine effects posted Recruiting No examine results posted Recruiting No study results posted Ongoing Ginzler eM, 2014 Recruiting No study results posted Recruiting No review success posted Recruiting No study final results posted Finished No review outcomes posted Terminated No study results posted Oct-11 Recruiting No review final results posted No review benefits posted Dec-11 No examine results posted Aug-12 Response fee (safetyefficacy research) Proof of notion of efficacy of belimumab in subjects with SSBLiSS-NCT00424476 NCT01597492 NCT01532310 NCTincidence of adverse events of special interest % transform at SeLeNA-SLeDAi at week 24 (safety and efficacy) incidence of all-cause mortality (52 weeks) Variety of participants that has a renal response at week 104 SRi response price subcutaneous administration Response charge at 52 weeks black race Long-term safety of belimumab in SLe Responder fee at week 52 Belimumab treatment holiday and treatment restart study in lupus sufferers SRi pediatric lupus Long-term safety of LymphoStat-BTM in SLe SRi response rate at week 52 in SLe pts positioned in Northeast Asia Long-term safety of belimumab in topics with SLe in Northeast Asia Suitability with the autoinjector for self-administration of belimumab by topics with SLe Efficacy and security in a subgroup of SLE patients: pooled information from your BLISS-52 and BLISS-submit your manuscript | dovepressNCT01729455 Key endpoint NCT00071487 not met NCT01705977 NCT01639339 NCT01484496 NCT01632241 NCT00712933 Pooled NCT01914770 NCT02119156 NCT01649765 NCT00583362 NCT01345253 NCT01597622 NCT02124798 NCT01858792 Vasculitis BRevAS NCT01663623 RA Mild efficacy NCT00071812 Scleroderma Diffuse reduce SScl NCT01670565 Transplantation NCT01025193 NCT01536379 Sj ren’s syndrome BeLiSS NCT01160666 NCTDesensitization in advance of kidney transplant Prevention of α9β1 site allograft rejection in adult topics right after renal transplantation (pilot, single center)Focusing on BAFF for that treatment of AAvDovepressAbbreviations: Ae, adverse occasion; BAFF, B-cell-activating element in the TNF family members; BRevAS, Belimumab in Remission of vasculitis; igG, immunoglobulin G; RA, rheumatoid arthritis; SLe, systemic lupus erythematosus; SRi, SLe responder index; SS, Sj ren’s syndrome.Lenert and LenertDovepressTable 4 Clinical trials with tabalumab and blisibimodClinical trial SLE NCT02041091 NCT01196091 NCT01205438 NCT01488708 NCT01676701 NCT00689728 NCT00785928 NCT01253226 NCT01576549 NCT00308282 NCT01198002 NCT01202760 NCT01202773 NCT00.